• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

‘No More Paying For The Rich World’s Medicine’ – White House

13/02/2019 by Intellectual Property Watch 4 Comments

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

The Trump administration yesterday made some firm statements about reducing health care and drug prices for American consumers and making costs more transparent. The statements again appear to focus on other countries paying more for US-made drugs but also promote generic drugs.

Below is an item from 12 February on the 1600 Daily blog:

No more paying for the rich world’s medicine

After today’s Cabinet meeting, Health and Human Services Secretary Alex Azar took a moment to explain how America’s seniors are footing the drug bills for patients in some of the richest countries in the world.

“So under President Trump, what we’ve found is that in our Medicare program for senior citizens, for the drugs that doctors administer in their offices to patients . . . we’re paying 180 percent of what the Europeans, the Canadians, and the Japanese are paying for the exact same drugs,” Secretary Azar says. “Pharma is making all their profit here in the United States, and then they’re giving these sweetheart deals in the other countries.”

Putting American patients first has been core to President Trump’s agenda since day one. Last week, during his second State of the Union address, he called on Congress to join him: “The next major priority for me, and for all of us, should be to lower the cost of healthcare and prescription drugs, and to protect patients with preexisting conditions.”

Already, President Trump’s efforts to put patients in control have resulted in the single largest decline in drug prices in 46 years. The FDA approved a record number of generic drugs in 2017 and 2018 as alternatives to expensive brand-name medicines. All told, these approvals have saved customers a staggering $26 billion.

The next chapter in the fight against high drug prices is increasing transparency and ending the practice of global free-riding. Hospitals, insurance companies, and drug companies should be required to disclose real prices to patients to drive costs down. And Americans must get a share of whatever discounts other wealthy countries receive.

“This is wrong, this is unfair, and together we will stop it,” President Trump said last Tuesday. “And we’ll stop it fast.”

Watch: It’s time to stop paying for the rich world’s medicine.

Read: “How Team Trump is bringing drug prices down”

For years, the pharma industry has profited by charging American patients more while giving sweetheart deals to other countries across the globe.

No more. The days of America paying for the rich world's medicine are over.

1600 Daily: https://t.co/A68ueVC88u pic.twitter.com/TLPX6Mldc1

— The White House (@WhiteHouse) February 13, 2019

Image Credits: White House

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"‘No More Paying For The Rich World’s Medicine’ – White House" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Themes, Venues, English, Health & IP, North America, Patents/Designs/Trade Secrets, Regional Policy

Trackbacks

  1. TV drug ads will soon include prices: Will it help consumers? – American News says:
    19/02/2019 at 9:39 pm

    […] this month, U.S. Health and Human Services Secretary Alex Azar said during a cabinet meeting that the Medicare program overpays for its prescription drugs compared to other countries such as […]

    Reply
  2. TV drug ads will soon include prices: Will it help consumers? – Todays Healthy Lifestyle says:
    21/03/2019 at 6:30 pm

    […] this month, U.S. Health and Human Services Secretary Alex Azar said during a cabinet meeting that the Medicare program overpays for its prescription drugs compared to other countries such as […]

    Reply
  3. TV drug ads will soon include prices: Will it help consumers? - says:
    15/05/2019 at 1:58 am

    […] this month, U.S. Health and Human Services Secretary Alex Azar said during a cabinet meeting that the Medicare program overpays for its prescription drugs compared to other countries such […]

    Reply
  4. TV drug ads will soon include prices: Will it help consumers? – News Tested says:
    05/09/2019 at 12:18 am

    […] this month, U.S. Health and Human Services Secretary Alex Azar said during a cabinet meeting that the Medicare program overpays for its prescription drugs compared to other countries such as […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.